Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00421317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imatinib in Adult Patients With Metastatic Ocular Melanoma

Study acronym: O-Mel-Inib
StatusTerminated
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Mar 2007 to Nov 15, 2009v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Recruiting to Terminated Sponsor's reason: Study stopped at the end of the first step Enrollment target: 32 to 13 · Study sites: 10 to 12 · Primary completion date: Mar 2007 · 2 morev2 Show 5 more changesShow less
    • Enrollment target: 32 to 13
    • Study sites: 10 to 12
    • Primary completion date: Mar 2007
    • Completion date: Jan 2009 to Mar 2007
    • Collaborators expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Centre Oscar Lambret
100 trials monitored
See 2 trials at risk
Melanoma
1,026 trials monitored
See 47 trials at risk
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Trial Details
NCT Number NCT00421317
Lead Sponsor Centre Oscar Lambret
Collaborators: Novartis, National Cancer Institute, France
Conditions Melanoma
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov